April 2016 ASX Compliance Pty Ltd 20 Bridge Street Sydney NSW 2000 Prima BioMed Ltd ASX Price Query Response I refer to your letter dated 21 April 2016 in relation to the ASX price query. Prima BioMed Limited ( Prima Bio

Prima BioMed Ltd ASX Price Query Response

refer to your letter dated 21 April 2016 in relation to the ASX price query. Prima BioMed Limited (Prima BioMed) provides the following responses to the questions in your letter.

Response. No, Prima BioMed is not aware of any such information.

Response. Prima BioMed is aware that it has recently been the subject of a favourable research report by Maxim Group, available on the

Prima BioMed website.

Response. Prima BioMed is compliant with the Listing Rules, including Listing Rule 3.1

Prima Biomed Ltd (the Entity ): ASX price query

We have noted a change in the price of the Entity s securities from a close of $0.04 on Wednesday, 20 April 2016 to a high of $0.049 today,

Thursday, 21 April 2016.

We also note an increase in the trading volume of the Entity s securities.

In light of the price and volume increase, ASX asks you to respond separately to each of the following questions:

Please note that the recent trading in the Entity s securities would suggest to ASX that such information may have ceased to be

confidential and therefore the Entity may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is yes , you need to contact us immediately to discuss the situation.

Please note, if the answer to this question is

no , you need to contact us immediately to discuss requesting a trading halt (see below).

When and where to send your response

made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than 2.00 p.m. AEST) on Thursday 21 April 2016. If we do not have your response by then, ASX will

have no choice but to consider suspending trading in the Entity s securities under Listing Rule 17.3.

You should note that if the information

requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, the Entity s obligation is to disclose the information

immediately . This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right

to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your

response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rule 3.1 requires a listed

entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity s securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

The obligation of the Entity to disclose information under Listing Rules 3.1 and 3.1A is not confined to, nor is it necessarily satisfied by, answering the

questions set out in this letter.

In responding to this letter, you should have regard to the Entity s obligations under Listing Rules 3.1 and 3.1A

and also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 3.1B.

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is yes and an announcement cannot be made

immediately, you should discuss with us whether it is appropriate to request a trading halt in the Entity s securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 Trading Halts & Voluntary Suspensions.

If you have any queries or concerns about any of the above, please contact me immediately.

[Sent electronically without signature]

Senior Adviser, Listings Compliance